Adaptimmune Therapeutics PLC (ADAP)

NASDAQ: ADAP · IEX Real-Time Price · USD
1.08
-0.07 (-6.52%)
At close: Sep 30, 2022 4:00 PM
1.15
+0.07 (6.98%)
After-hours: Sep 30, 2022 7:53 PM EDT
-6.52%
Market Cap 175.62M
Revenue (ttm) 11.73M
Net Income (ttm) -176.04M
Shares Out 163.37M
EPS (ttm) -1.09
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 314,129
Open 1.08
Previous Close 1.15
Day's Range 1.01 - 1.09
52-Week Range 1.01 - 5.95
Beta 1.75
Analysts Buy
Price Target 5.95 (+453.5%)
Earnings Date Aug 4, 2022

About ADAP

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS); in phase II clinical trials with SPEARHEAD-2 for patients with head and n... [Read more...]

Industry Biotechnology
IPO Date May 6, 2015
Employees 494
Stock Exchange NASDAQ
Ticker Symbol ADAP
Full Company Profile

Financial Performance

In 2021, ADAP's revenue was $6.15 million, an increase of 55.36% compared to the previous year's $3.96 million. Losses were -$158.09 million, 21.5% more than in 2020.

Financial Statements

Analyst Forecast

According to 14 analysts, the average rating for ADAP stock is "Buy." The 12-month stock price forecast is 5.95, which is an increase of 453.49% from the latest price.

Price Target
$5.95
(453.49% upside)
Analyst Consensus: Buy
Stock Forecasts

News

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Adaptimmune Therapeutics plc - ADAP

New York, New York--(Newsfile Corp. - September 17, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Adaptimmune Therapeutics plc ("Adaptimmune" or the "Company") (NASDAQ: ADAP). ...

2 weeks ago - Newsfile Corp

Adaptimmune Reports Positive Data in its SURPASS Trial; Outlines Plans for Advanced Clinical Development in Multiple ...

- 44% Objective Response Rate (ORR) with a single dose of ADP-A2M4CD8 in 25 heavily pre-treated patients with late-stage ovarian, urothelial, and head & neck cancers -- Further clinical development plan...

3 weeks ago - Newsfile Corp

Adaptimmune to Host Live, Virtual Event to Review Phase 1 SURPASS Trial Data and Outline Plans for Further Developmen...

- Event to be held on Friday, September 9th, at 8 a.m. EDT -Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - August 25, 2022) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a lea...

1 month ago - Newsfile Corp

Adaptimmune Reports Second-Quarter Financial Results and Business Update

- Reaffirming financial guidance; Company funded into early 2024 -- ASCO data confirms afami-cel potential for synovial sarcoma; BLA submission on-track for Q4 2022 - - Update from signal-finding Phase ...

1 month ago - Newsfile Corp

Adaptimmune to Report Q2 2022 Financial Results and Business Updates on Thursday, August 4, 2022

Philadelphia, Pennsylvania and Oxfordshire, United Kingdom--(Newsfile Corp. - July 21, 2022) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, will report financia...

2 months ago - Newsfile Corp

Got $500? 3 Absurdly Cheap Healthcare Stocks That Are Set to Skyrocket

Here's why these Fool.com contributors are bullish on Adaptimmune Therapeutics, G1 Therapeutics, and Axsome Therapeutics.

Other symbols: AXSMGTHX
3 months ago - The Motley Fool

Why Adaptimmune Therapeutics Stock Is Popping Today

Buyout fever is sparking interest in the biotech's beaten-down shares today.

3 months ago - The Motley Fool

Clinical Responses Reported across Patient Subgroups with Adaptimmune's Cell Therapy, Afami-cel, Confirming Potential...

- Patients who responded to afami-cel had longer progression-free survival (median 58 weeks) compared to non-responders (median 12 weeks) -- Responses occurred across subgroups, with greater response ra...

4 months ago - Newsfile Corp

Why Shares of Adaptimmune Therapeutics Rose 13.4% on Tuesday

The clinical-stage biotech saw its shares rise after releasing preclinical data on two of its therapies.

4 months ago - The Motley Fool

Preclinical Proof-of-Concept Data Supporting Future Clinical Development of Two New Cell Therapies Being Presented by...

- New next-gen SPEAR T-cells (ADP-A2M4N7X19) designed to enhance depth and durability of clinical response demonstrated enhanced proliferation, survival, and recruitment of immune cells in vitro -

4 months ago - GlobeNewsWire

Adaptimmune Reports First Quarter Financial Results and Business Update

- Pooled data from Cohort 1 of the SPEARHEAD-1 trial and the Phase 1 trial of afami-cel in patients with sarcoma to be presented as a poster at ASCO -

4 months ago - GlobeNewsWire

Adaptimmune Announces Appointment of Joanna Brewer as Chief Scientific Officer

PHILADELPHIA and OXFORDSHIRE, United Kingdom, May 04, 2022 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announces the appointment of ...

4 months ago - GlobeNewsWire

Adaptimmune to Report Q1 2022 Financial Results and Business Updates on Monday, May 9, 2022

PHILADELPHIA and OXFORDSHIRE, United Kingdom, April 28, 2022 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results and p...

5 months ago - GlobeNewsWire

New Strong Sell Stocks for April 26th

ANIK, ALIM, and ADAP have been added to the Zacks Rank #5 (Strong Sell) List on April 26, 2022

Other symbols: ALIMANIK
5 months ago - Zacks Investment Research

New Strong Sell Stocks for April 22nd

BBBY, CLGN, and ADAP have been added to the Zacks Rank #5 (Strong Sell) List on April 22, 2022

Other symbols: BBBYCLGN
5 months ago - Zacks Investment Research

Why Adaptimmune Therapeutics, Agenus, and Sorrento Therapeutics Popped Today

Regeneron's buyout of Checkpoint Pharmaceuticals is sparking a rally among clinical-stage cancer research companies today.

Other symbols: AGENSRNE
5 months ago - The Motley Fool

Why Adaptimmune Therapeutics Shares Dropped 14.7% on Monday

Investors were not pleased that the company is preparing for a stock sale.

5 months ago - The Motley Fool

New Strong Sell Stocks for April 11th

DDD, ADAP, and AKYA have been added to the Zacks Rank #5 (Strong Sell) List on April 11, 2022.

Other symbols: AKYADDD
5 months ago - Zacks Investment Research

Adaptimmune Presents MAGE-A4 Expression Data from its Screening Protocol at AACR Confirming Expression Across a Broad...

- Data from multiple solid tumor indications confirms that MAGE-A4 is a broadly expressed cancer target for SPEAR T-cell therapy -

5 months ago - GlobeNewsWire

New Strong Sell Stocks for March 25th

DDD, ADAP, and ADV have been added to the Zacks Rank #5 (Strong Sell) List on March 25, 2022.

Other symbols: ADVDDD
6 months ago - Zacks Investment Research

New Strong Sell Stocks for March 17th

DDD, ADAP, and AKYA have been added to the Zacks Rank #5 (Strong Sell) List on March 17, 2022.

Other symbols: AKYADDD
6 months ago - Zacks Investment Research

Adaptimmune Reports Fourth Quarter and Full Year 2021 Financial Results and Business Update

- SPEARHEAD-1 met its primary endpoint - planning for afami-cel BLA submission in Q4 2022 for people with synovial sarcoma -

6 months ago - GlobeNewsWire

Adaptimmune to Report Q4 and Full Year 2021 Financial Results and Business Updates on Monday, March 14, 2022

PHILADELPHIA and OXFORDSHIRE, United Kingdom, March 08, 2022 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results and p...

6 months ago - GlobeNewsWire

After Plunging 19.1% in 4 Weeks, Here's Why the Trend Might Reverse for Adaptimmune Therapeutics PLC (ADAP)

The heavy selling pressure might have exhausted for Adaptimmune Therapeutics PLC (ADAP) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall...

7 months ago - Zacks Investment Research

Adaptimmune Announces Appointment of Cintia Piccina as Chief Commercial Officer

PHILADELPHIA and OXFORDSHIRE, United Kingdom, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announces the appointment of...

8 months ago - GlobeNewsWire